Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Cash: 2009-2024

Historic Change in Cash for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to -$15.7 million.

  • Anika Therapeutics' Change in Cash rose 1162.33% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.4 million, marking a year-over-year increase of 47.14%. This contributed to the annual value of -$15.7 million for FY2024, which is 16.70% down from last year.
  • According to the latest figures from FY2024, Anika Therapeutics' Change in Cash is -$15.7 million, which was down 16.70% from -$13.5 million recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' Change in Cash ranged from a high of -$1.4 million in FY2021 and a low of -$61.6 million during FY2020.
  • Moreover, its 3-year median value for Change in Cash was -$13.5 million (2023), whereas its average is -$12.4 million.
  • In the last 5 years, Anika Therapeutics' Change in Cash soared by 97.68% in 2021 and then slumped by 463.17% in 2022.
  • Yearly analysis of 5 years shows Anika Therapeutics' Change in Cash stood at -$61.6 million in 2020, then skyrocketed by 97.68% to -$1.4 million in 2021, then crashed by 463.17% to -$8.1 million in 2022, then slumped by 67.02% to -$13.5 million in 2023, then fell by 16.70% to -$15.7 million in 2024.